A recent case underscores the effectiveness of integrating photobiomodulation into the supportive care regimen for patients on talquetamab, with sessions every 48 hours leading to resolution of treatment-related dysgeusia. This strategic recommendation is rooted in consistent evidence supporting PBM’s benefits, indicating a low risk posture for patients and enhancing their overall quality of life. Continued collection of patient-reported outcomes and safety data will further validate this innovative approach.